Gene · 1828
Papers3,287
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,287
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Serologic Biomarkers in Pemphigus Monitoring: C-reactive Protein, Macrophage Migration Inhibitory Factor, and Prolactin Levels Versus Autoantibody Assays. | Iran J Allergy Asthma Immunol | 2023 | 37524667 | PubTator, text mining | PubMed |
| Ultrastructural skin alterations of healthy subjects with anti-desmoglein 1 antibodies in endemic areas to pemphigus foliaceus: A case series. | J Transl Autoimmun | 2023 | 37520889 | PubTator, text mining | PubMed |
| Skin models of cutaneous toxicity, transdermal transport and wound repair. | Burns Trauma | 2023 | 37520659 | PubTator, text mining | PubMed |
| Intravenous Immunoglobulin for Autoimmune Bullous Diseases: A Case Series from a Central European Referral Center. | Medicina (Kaunas) | 2023 | 37512078 | PubTator, text mining | PubMed |
| Calpain Regulation and Dysregulation-Its Effects on the Intercalated Disk. | Int J Mol Sci | 2023 | 37511485 | PubTator, text mining | PubMed |
| Exosome from IFN-γ-Primed Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Improved Skin Inflammation and Barrier Function. | Int J Mol Sci | 2023 | 37511392 | PubTator, text mining | PubMed |
| Plasma Exosomal microRNA Profile Reveals miRNA 148a-3p Downregulation in the Mucosal-Dominant Variant of Pemphigus Vulgaris. | Int J Mol Sci | 2023 | 37511259 | PubTator, text mining | PubMed |
Efficacy of anti-desmoglein 1 and anti-desmoglein 3 levels by enzyme-linked immunosorbent assay compared to biopsy of chronic oral ulcerative diseases with positive Nikolsky's sign to diagnose oral pemphigus vulgaris with or without skin involvement: a retrospective institutional observational pilot study. | Oral Surg Oral Med Oral Pathol Oral Radiol | 2023 | 37507320 | PubTator, text mining | PubMed |
| Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review. | Front Immunol | 2023 | 37503352 | PubTator, text mining | PubMed |
| Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. | Front Immunol | 2023 | 37503332 | PubTator, text mining | PubMed |
| Co-circulation and co-infection of hantaviruses and Wenzhou mammarenavirus in small mammals and humans in Jiangxi, China. | Front Microbiol | 2023 | 37502398 | PubTator, text mining | PubMed |
| Pemphigus vulgaris after the second dose of COVID-19 vaccination: a case report. | J Med Case Rep | 2023 | 37496035 | PubTator, text mining | PubMed |
| The minichromosome maintenance complex drives esophageal basal zone hyperplasia. | JCI Insight | 2023 | 37490338 | PubTator, text mining | PubMed |
| Two cases of cutaneous-type pemphigus vulgaris and a case of pemphigus foliaceus without mucosal involvement despite high anti-desmoglein 3 autoantibody levels. | J Dermatol | 2023 | 37485682 | PubTator, text mining | PubMed |
| Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology. | Cureus | 2023 | 37485224 | PubTator, text mining | PubMed |
| A Case of Coma Bullae Associated with Brachioradial Artery. | Clin Cosmet Investig Dermatol | 2023 | 37483472 | PubTator, text mining | PubMed |
| Pemphigus vulgaris and focal segmental glomerulosclerosis (FSGS): First reported case and a review of the literature. | Clin Case Rep | 2023 | 37476592 | PubTator, text mining | PubMed |
| Transcriptional profiling of rare acantholytic disorders suggests common mechanisms of pathogenesis. | JCI Insight | 2023 | 37471166 | PubTator, text mining | PubMed |
| Adult eosinophilic esophagitis and advances in its treatment. | World J Methodol | 2023 | 37456973 | PubTator, text mining | PubMed |
| Food allergy: cause or consequence of pediatric eosinophilic esophagitis? Potential implications of ultraprocessed foods in prevention and management. | Front Allergy | 2023 | 37456790 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1828/papers?page=18